• Chen Qi Zhang, Xue Yang Bai, Yong Wan, Hong Yan Li, and Hongbin Sun.
• Department of Special Medical, Chengdu BOE Hospital, Chengdu, Sichuan Province, China.
• Medicine (Baltimore). 2021 Dec 17; 100 (50): e28290e28290.

BackgroundA novel once-daily divalproex-extended release (VPA-ER) dose formulation has been developed, which prolongs therapeutic serum levels compared with that of twice-daily conventional divalproex-delayed release (VPA-DR). Currently, there is lack of meta-analysis focusing on drug retention rate between VPA-ER and VPA-DR. Thus, our study is the first one that aims to systematically examine and compare the efficacy, safety, and retention rate of VPA-ER and VPA-DR.MethodsOnline databases including MEDLINE via PubMed, Cochrane Library, Embase (up to October 30, 2021) will be applied for literature screen. We will conduct meta-analysis by using Stata16.0 software.ResultsThis study aims to evaluate the efficacy, safety, and drug retention rate of VPA-ER versus conventional VPA-DR.ConclusionOnce-daily VPA-ER may present a positive efficacy and not increase the incidence of AEs and has a higher retention rate for patients, which can be used as a substitute for conventional VPA-DR.INPLASY registration number: INPLASY2021110090(DOI: 10.37766/inplasy2021.11.0090).Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

20 keywords...

hide…